The present invention is a respiratory system protection product and a method for creating said product. The product is created by separating an aloe vera gel from a quantity of aloe vera leaves. The aloe vera gel is added to a heating vessel. A first solution is prepared and added to cover the aloe vera gel. The heating vessel is covered, heated, and stirred until boiling, then removed from heat. After cooling to room temperature an oil component is added. The mixture is blended and amalgamated, then filtered to remove solid materials.

The present disclosure relates to a method for producing a purified cannabaceae biomass extract, wherein a crude alcoholic cannabaceae biomass extract comprising at least two cannabinoid compounds in an alcoholic solvent is circulating through a powdered layer of activated carbon and the purified cannabaceae biomass extract is recovered with a ratio of cannabinoid compounds in the purified cannabaceae biomass extract is higher than the ratio of the cannabinoid compounds in the crude alcoholic cannabaceae biomass extract.

The present invention relates to a composition for preventing sleep disorders or insomnia, containing an enzyme-treated Ashwagandha extract as an active ingredient, and specifically, since it was confirmed that in an animal model and a sleep disorder animal model, which were administered an enzyme-treated Ashwagandha extract, sleep latency and awake time during sleep were decreased, sleep time, non-rapid eye movement (NREM) sleep time and δ-waves were increased, and as a result, sleep activity was improved, the enzyme-treated Ashwagandha extract can be used as an active ingredient of a composition for preventing or treating sleep disorders or insomnia.

A traditional Chinese medicine compound preparation for treating Parkinson's disease and its preparation method and application are disclosed. The traditional Chinese medicine compound preparation comprises traditional Chinese medicine formula components and the traditional Chinese medicine formula components comprise the following raw material or raw material extracts by mass: 6-15 parts of uncaria rhynchophylla, 3-9 parts of gastrodia elata, 6-12 parts of Gentiana macrophylla, 10-20 parts of raw astragalus membranaceus, 10-20 parts of prepared rehmannia roots, 10-20 parts of achyranthes roots, 10-20 parts of wolfberry fruits, 10-20 parts of angelica sinensis, 10-20 parts of fried atractylodes macrocephala, 6-15 parts of fried spina date seeds, 3-12 parts of walnut kernels, 3-9 parts of safflower, and 20-30 parts of zaocys dhumnade.

Invention deals with a macular carotenoid formulation comprising Carotenoids, Lutein, Zeaxanthin, Meso Zeaxanthin, Beta Carotene, Alpha Carotene, Lycopene and Cryptoxanthin in a synergistic combination. The formulation helps in increasing macular pigment optical density (MPOD) related to prevention of age-related macular degeneration (ARMD). The formulation is used as a nutrient, nutraceutical or dietary supplement. The dietary supplement may be formulated as soft gel capsules, two-piece hard-shell capsules, liquid-fill capsules, tablets, effervescent granules, gummies, powder mixes, stick packs, beverages, emulsions, bakery products, dairy products, tinctures, oil suspensions, bead-lets, powders, cold water-soluble powders, emulsions and granules or any combination thereof. The present invention can be used for the development of functional food, dietary plan and as a nutritional supplement. In exemplary embodiment, formulation is available in forms like oil suspension, beadlets, powders, cold water-soluble powders, emulsions and granules.

A method for preparing a Plectranthus amboinicus (PA) extract, the method comprising extracting an above-ground part of Plectranthus amboinicus with an extracting solution that comprises a solvent having a suitable polarity index, filtrating and concentration the extract thus produced, and subject the concentrated extract to a chromatographic separation process using a hydrophobic interaction chromatography resin to produce the PA extract.

The present disclosure relates to the isolation, preservation, compositions and uses of extracts from a newly discovered species of Justicia plants. The present disclosure also relates to compositions comprising the extracts of the new species of Justicia plant, as well as methods of producing and using such compositions for treating blood disorders and/or for other health, food and industrial uses.

The present invention addresses the problem of providing a novel composition having the effect of improving a mental state. The present invention pertains to: a composition that is for improving a mental state, and that contains, as an active ingredient, a water-soluble component of the fruit of eggplant (Solanum melongena); and a production method that is for an eggplant-derived composition for improving a mental state, and that comprises squeezing an eggplant fruit to obtain a juice, or adding water to an eggplant fruit and squeezing the fruit to which water has been added, to obtain a juice.

This disclosure describes extraction methods that allow for the release of large amounts of phytochemicals (e.g., cannabinoids) into a lipid phase, resulting in a high yield method, even in the absence of any organic solvents. As described herein, a naturally occurring lipid phase (e.g., from oilseeds) can be used.

Cannabidivarin (CBDV) is a cannabinoid designated chemically as 2-[(1R,6R)-3-Methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-propyl-1,3-benzenediol. Its empirical formula is C19H26O2 and its molecular weight is 286.4 g/mol. CBDV is a cannabinoid that naturally occurs in the Cannabis sativa L. plant. CBDV is an off-white to pale yellow crystalline solid which is insoluble in water and soluble in organic solvents. The present invention encompasses the surprising recognition that certain CBDV preparations which are prepared from a botanical origin are more effective in treating diseases or disorders than preparations of CBDV which are synthetic or purified to the extent no other impurities in the form of other cannabinoids are present. Prior CBDV compositions have been prepared such that no psychoactive components, e.g., tetrahydrocannabinol (THC), remain in the final CBDV preparation. Surprisingly, the absence of such minor impurities reduces the efficacy of CBDV treatment. Such CBDV preparations are characterized by chemical components and/or functional properties that distinguish them from prior CBDV compositions. One or more components of the preparations described herein provide an unexpectedly synergistic effect when utilized in combination.